Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Veloxis Pharmaceuticals

Request full access

Speciality pharmaceutical company focused on the development and commercialization of Envarsus

Cary, United StatesFounded 2002Biotech & Life Sciences

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals operates as a specialty pharmaceutical company with a dedicated focus on the post-transplantation market. The company's origins trace back to its founding in 2002 as a Danish entity, initially listed on the Nasdaq Copenhagen stock exchange. A significant turning point in its history occurred in 2020 when Asahi Kasei, a Japanese chemical company, acquired Veloxis in a transaction valued at approximately $1.3 billion, leading to its delisting and integration into the broader Asahi Kasei Group.

The company's core business revolves around the development and commercialization of therapeutic solutions for transplant patients. Its flagship product is Envarsus XR®, a once-daily tablet formulation of tacrolimus, an immunosuppressant drug. This product is specifically designed to prevent organ rejection in patients who have undergone a kidney transplant. The primary benefit of the Envarsus XR formulation is its extended-release mechanism, which allows for a single daily dose, contrasting with other tacrolimus products that may require twice-daily administration. This simplified dosing regimen is intended to improve patient adherence and convenience.

Veloxis's business model is that of a fully integrated pharmaceutical company, handling everything from clinical development and regulatory approvals to manufacturing and commercial sales. The company generates revenue through the sale of its approved products, primarily Envarsus XR®, in the markets where it has received authorization, including the United States and Europe. Its target clients are transplant centers, physicians, and the patients they serve. By concentrating on the niche market of transplant medicine, Veloxis addresses the specific and ongoing needs of this patient population for effective and manageable immunosuppressive therapies.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2006
Outcome tier
Unicorn$1–10B valuation tier

Veloxis Pharmaceuticals in the Cary ecosystem

Live from Dealroom

The Veloxis Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Athyrium Capital Management
Team profiled 18 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States99%
🇯🇵 Japan1%
2 countries shown
Web traffic by country
4K monthly visits
across markets
🇺🇸 United States75%
🇮🇳 India10%
🇯🇵 Japan2.5%
Top 3 markets shown

Patents

Estimated portfolio value
$86M

29 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Veloxis Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Veloxis Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.